WO2022259526A1 - エクソソーム産生促進剤及びエクソソーム産生促進方法 - Google Patents
エクソソーム産生促進剤及びエクソソーム産生促進方法 Download PDFInfo
- Publication number
- WO2022259526A1 WO2022259526A1 PCT/JP2021/022314 JP2021022314W WO2022259526A1 WO 2022259526 A1 WO2022259526 A1 WO 2022259526A1 JP 2021022314 W JP2021022314 W JP 2021022314W WO 2022259526 A1 WO2022259526 A1 WO 2022259526A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- mesenchymal stem
- exosome production
- exosome
- adipose
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 95
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 55
- 230000001737 promoting effect Effects 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 13
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 51
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 17
- 239000012679 serum free medium Substances 0.000 claims abstract description 13
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims abstract description 10
- 101000942297 Homo sapiens C-type lectin domain family 11 member A Proteins 0.000 claims abstract description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 9
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 238000002316 cosmetic surgery Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 13
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000000835 fiber Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- -1 MEMα Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 230000003416 augmentation Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000009832 plasma treatment Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- CRSBERNSMYQZNG-UHFFFAOYSA-N 1-dodecene Chemical compound CCCCCCCCCCC=C CRSBERNSMYQZNG-UHFFFAOYSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadec-1-ene Chemical compound CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101710106459 29 kDa protein Proteins 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical compound CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- 206010059109 Cerebral vasoconstriction Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000000979 Erythema Induratum Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000002325 Funnel Chest Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940069096 dodecene Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Definitions
- the present invention relates to an exosome production promoter that promotes exosome production from mesenchymal stem cells, and a method for promoting exosome production.
- MSCs Mesenchymal stem cells
- mesenchymal stem cells secrete cytokines and growth factors that have anti-inflammatory, cell proliferation-promoting, and angiogenesis-promoting effects in an undifferentiated state, and support tissue repair via paracrine.
- Non-Patent Document 1 Molecules secreted by undifferentiated mesenchymal stem cells have therapeutic effects not only on specific limited diseases but also on various diseases.
- Tissue regeneration can be achieved by using naive mesenchymal stem cells without inducing the differentiation of mesenchymal stem cells into cells of the tissue to be repaired, and without adding any artificial manipulation such as genetic recombination to the cells. It becomes possible.
- Exosomes can mediate communication between cells by transferring proteins, lipids and RNA between cells (Non-Patent Documents 2 and 3). It has been found that molecules such as proteins, microRNAs, and mRNAs contained in exosomes have functions similar to those of the cells from which they are derived. Therefore, exosomes secreted by mesenchymal stem cells, which are attracting attention as a source of cell therapy for a wide range of diseases, are expected to have therapeutic effects similar to MSCs (Non-Patent Document 4).
- Patent Document 1 describes exosomes isolated from a cultured neural stem cell line (NSCL).
- the exosomes can promote fibroblast migration, human umbilical vein endothelial cell branching, and neurite outgrowth.
- Exosomes contain relatively less animal serum than stem cells, and the risk of symptoms due to animal serum infection can be eliminated. Therefore, exosome-based cell therapy can overcome the limitations of existing stem cell therapies.
- Patent Document 2 discloses an exosome production promoter containing a sphingoid base as an active ingredient.
- the exosome production promoter described in Patent Document 2 is limited to those that can promote the production of exosomes in nerve cells to cure Alzheimer's disease.
- mesenchymal stem cells their phenotype, differentiation capacity, immunological features, and potential for homing.
- the present invention has been made in view of such problems, and aims to provide an exosome production promoter and a method for promoting exosome production that promote the production of exosomes from adipose-derived mesenchymal stem cells.
- the exosome production promoter according to the present invention is an exosome production promoter that promotes the production of exosomes from adipose-derived mesenchymal stem cells cultured in a serum-free medium, and is characterized by having EGF.
- the method for promoting exosome production according to the present invention is a method for promoting exosome production that promotes the production of exosomes from adipose-derived mesenchymal stem cells, and comprises culturing adipose-derived mesenchymal stem cells in a serum-free medium containing EGF. Characterized by
- the production of exosomes from adipose-derived mesenchymal stem cells could be promoted.
- the exosome production promoter of the present invention promotes exosome production from adipose-derived mesenchymal stem cells cultured in serum-free medium.
- the adipose-derived mesenchymal stem cells are preferably human adipose-derived mesenchymal stem cells. Compared with bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells have advantageous characteristics such as faster cell proliferation, more secretion of regeneration-promoting factors, and higher immunosuppressive ability. Furthermore, since adipose-derived mesenchymal stem cells can be obtained from adipose tissue in the abdomen or buttocks, compared with bone marrow-derived mesenchymal stem cells that require collection of bone marrow, it is advantageous in that it is easier to secure a sufficient amount safely.
- mesenchymal stem cells derived from the patient's own adipose tissue for the treatment of the patient has no ethical problems, no immune rejection, few problems such as infections, and is effective for intravenous administration. etc., are excellent.
- Adipose-derived mesenchymal stem cells are positive for CD73, CD90, CD105 and CD44, and negative for CD11b, CD19, CD34, CD45 and HLA-DR.
- Adipose tissue-derived mesenchymal stem cells have the ability to differentiate into, for example, osteoblasts, adipocytes, and chondrocytes.
- Adipose tissue-derived mesenchymal stem cells are obtained by separating mesenchymal stem cells from adipose tissue, primary culturing the mesenchymal stem cells in a serum-containing medium, and culturing the mesenchymal stem cells subcultured from the primary culture in a serum-free medium. Obtained by proliferating and culturing.
- Adipose tissue is obtained, for example, by surgical resection from mammals such as humans. Local anesthesia may be used during surgical excision.
- adipose tissue may be obtained by aspiration by intubating a catheter into the subcutaneous adipose tissue of the abdomen, thigh, or buttocks.
- the amount of adipose tissue obtained is, for example, but not limited to, 1 g to 100 g, 2 g to 50 g, 2 g to 40 g, or 2 g to 20 g.
- adipose tissue is washed with, for example, physiological saline, immersed in a solution containing collagenase diluted to a concentration of 0.1% in Hank's balanced salt solution at 37°C for 70 minutes, and dispersed.
- Adipose tissue-derived cells dispersed from adipose tissue are centrifuged at 1800 rpm for 10 minutes.
- the interstitial vascular cell cluster obtained by centrifugation is diluted with a solution and filtered through a 100 ⁇ m nylon mesh. Filtered cells are washed with MEM ⁇ .
- the serum-free medium is a serum-free medium for mesenchymal stem cells, such as DMEM, MEM ⁇ , DMEM/F12, and MEM.
- the exosome production promoter of the present invention has EGF.
- EGF is a factor that promotes the production of exosomes as a new finding, and completed the present invention based on this fact.
- EGF is a 6045 Da protein consisting of 53 amino acid residues and 3 intramolecular disulfide bonds. It binds to the epidermal growth factor receptor (EGFR) present on the cell surface as a ligand and plays an important role in regulating cell growth and proliferation.
- the content of EGF in the medium is not particularly limited, but the final concentration is preferably 0.05-300 ng/ml, more preferably 1-100 ng/ml.
- IL-1 ⁇ also promotes exosome production from adipose-derived mesenchymal stem cells, it is preferable that IL-1 ⁇ is also included.
- the content of IL-1 ⁇ in the medium is not particularly limited, but the final concentration is preferably 0.001-10 ng/ml, more preferably 0.01-1 ng/ml.
- Trehalose is included because trehalose also promotes the amount of exosomes produced from adipose-derived mesenchymal stem cells.
- Trehalose is a disaccharide composed of two ⁇ -glucoses linked 1,1-glycoside.
- the content of trehalose in the medium is not particularly limited, but the final concentration is preferably 1-50 mg/ml, more preferably 10-30 mg/ml.
- the exosome production promoter of the present invention does not contain SCGF.
- SCGF is a 29-kDa protein without N-glycans and belongs to the C-type lectin family.
- the exosome production promoter of the present invention does not include TNF ⁇ .
- adipose-derived mesenchymal stem cells are preferably cultured using a non-woven fabric as a scaffold. Exosome production is further promoted when adipose-derived mesenchymal stem cells are cultured using non-woven fabric as a scaffold.
- the nonwoven fabric may have a basis weight of 1 to 500 g/m 2 , for example, preferably 50 to 200 g/m 2 .
- the nonwoven fabric may be a hydrophilized nonwoven fabric. Hydrophilization of the nonwoven fabric can be performed by fluorine gas treatment, normal pressure plasma treatment, vacuum plasma treatment, corona treatment, hydrophilic monomer graft polymerization treatment, sulfonation treatment, or surfactant application treatment. Treatment, atmospheric pressure plasma treatment is preferred.
- Fibers constituting the nonwoven fabric are preferably polyolefin polymers, and examples of polyolefin polymers include ethylene, propylene, 1-butene, 1-pentene, 3-methyl-1-butene, 1-hexene, and 1-octene. , 1-dodecene, 1-octadecene and the like.
- the fibers that make up the nonwoven fabric are desirably fibers with a small fiber diameter, and the average fiber diameter is preferably 200 ⁇ m or less, more preferably 010 to 100 ⁇ m, and particularly preferably 15 to 50 ⁇ m.
- the fibers may include fibers having a relatively large fiber diameter and fibers having a relatively small fiber diameter.
- the nonwoven fabric is preferably porous. Porosity is important in terms of supplying sufficient oxygen and nutrients to cells necessary for tissue regeneration and expediting carbon dioxide and waste products. Moreover, by having porosity, the specific surface area is increased and the cell adhesiveness is enhanced.
- the average pore size in such cases is, for example, 5 ⁇ m to 200 ⁇ m, 20 ⁇ m to 100 ⁇ m, 25 ⁇ m to 100 ⁇ m, 30 ⁇ m to 100 ⁇ m, 35 ⁇ m to 100 ⁇ m, 40 ⁇ m to 100 ⁇ m, 50 ⁇ m to 100 ⁇ m, or 60 ⁇ m to 100 ⁇ m, preferably 50 ⁇ m to 300 ⁇ m. be.
- the form of the nonwoven fabric is not particularly limited, it is preferably a nonwoven fabric sheet.
- the nonwoven fabric sheet preferably has a plurality of through-holes penetrating in the thickness direction.
- the total thickness of the nonwoven fabric sheet may be, for example, 5 ⁇ m or more, 10 ⁇ m or more, 20 ⁇ m or more, or 25 ⁇ m or more, and may be 500 ⁇ m or less, 300 ⁇ m or less, 100 ⁇ m or less, 75 ⁇ m or less, or 50 ⁇ m or less. It is preferably 30 to 2000 ⁇ m, more preferably 500 to 1000 ⁇ m.
- Exosomes produced by using the exosome production promoter of the present invention can be used as exosome-containing preparations.
- the form of the exosome-containing formulation is not particularly limited, but may be, for example, an injection, a suspension, a solution, a liquid formulation such as a spray, or may be a sheet formulation or a gel formulation.
- the exosome-containing formulation is not limited in its usage, for example, it can be used for direct administration to a subject, or it can be used as a source for tissue or organ reconstruction performed in vitro. can.
- Exosome-containing preparations can be used to treat diseases or disorders.
- Diseases or disorders that can be targeted include immune diseases, ischemic diseases (leg ischemia, ischemic heart disease (myocardial infarction, etc.), coronary heart disease, cerebrovascular ischemia, renal ischemia, pulmonary ischemia, etc.), Neurological disease, Crohn's disease, graft-versus-host disease (GVHD), inflammatory bowel disease including ulcerative colitis, collagen disease including systemic lupus erythematosus, liver cirrhosis, cerebral infarction, intracerebral hematoma, cerebrovascular spasm, radiation enteritis , atopic dermatitis, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), scleroderma, degeneration and/or inflammation of connective tissues such as cartilage disease, eye
- exosome-containing preparations can also be used for treatment, treatment, or improvement for cosmetic purposes.
- Cosmetic purposes include not only cosmetic purposes purely for restoring a healthy state, but also cosmetic treatments for post-surgical or post-traumatic deformities and congenital deformities.
- it can be used for breast augmentation (breast augmentation, breast reconstruction), augmentation for cheek or upper and lower eyelid depressions, as well as hemifacial atrophy, facial or funnel chest augmentation.
- Exosome-containing preparations may contain pharmaceutically acceptable carriers and additives in addition to exosomes.
- carriers and additives include tonicity agents, thickeners, sugars, sugar alcohols, preservatives (preservatives), bactericides or antibacterial agents, pH adjusters, stabilizers, chelating agents. , oily base, gel base, surfactant, suspending agent, binder, excipient, lubricant, disintegrant, foaming agent, fluidizer, dispersant, emulsifier, buffer, solubilizer , antioxidants, sweeteners, acidulants, coloring agents, flavoring agents, flavoring agents or cooling agents, but are not limited to these.
- exosomes it is possible to stably supply large amounts of exosomes from adipose-derived mesenchymal stem cells.
- molecules with therapeutic effects such as mRNA, miRNA, and proteins in mesenchymal stem cells using gene recombination technology and producing exosomes loaded with those molecules, it is possible to apply them to various treatments and beauty treatments.
- exosomes can be delivered more specifically to target tissues by modifying the surface of exosomes by expressing receptors for proteins that are specifically expressed in target tissues on the surface of exosomes using genetic recombination technology. It is possible.
- ADSC adipose-derived mesenchymal stem cells
- a non-woven fabric (3D, BioNOCII, CESCO in non-adhesive 24-well plate (PrimeSurface (registered trademark) Sumitomo Bakelite) was used for cell culture.
- the basal medium was 1.5 ml of 10% FBS/DMEM F12 (Sigma).
- the number of culture days was 6. Starting from Day 2, the medium was changed by 1.5 ml every day, and the sugar consumption of the spent culture medium was measured.
- the medium was DMEM F12 in order to collect exosomes.
- 10% ExoFBS (Funakoshi) was added in test #1.
- ExoFBS is depleted of bovine-derived exosomes, reducing its impact on exosome research.
- all eight factors A to H were added at the concentrations shown in Table 1 below during the 48-hour culture.
- test #3 only factor A was removed from the 8 factors shown in Table 1 and the remainder was added; in test #4, only factor B was removed from the 8 factors shown in Table 1 and the rest were added; In test #5, remove only factor C from the 8 factors shown in Table 1 and add the rest; in test #6, remove only factor D from the 8 factors shown in Table 1 and add the rest; in test #7, add Table 1 In test #8, remove only factor F from the 8 factors shown in Table 1 and add the rest, and in test #9, add the remaining factors from the 8 factors shown in Table 1 Only G was removed and the remainder was added, and in test #10 only factor H was removed from the 8 factors shown in Table 1 and the remainder was added.
- the amount of exosomes produced from ADSCs was measured using an Exo Counter (Kenwood) from 1.5 ml of the collected culture supernatant to 50 ⁇ l each. ExoCounter detects exosomes by surface antigen-specific sandwich detection with antibodies on discs and nanobeads. The amount of exosomes was quantified by detecting CD81 on the surface of exosomes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (12)
- 無血清培地で培養される脂肪由来間葉系幹細胞からのエクソソームの産生を促進するエクソソーム産生促進剤であって、
EGFを有することを特徴とするエクソソーム産生促進剤。 - 更にIL-1βを包含することを特徴とする請求項1に記載のエクソソーム産生促進剤。
- 更にトレハロースを包含することを特徴とする請求項1又は2に記載のエクソソーム産生促進剤。
- SCGFを包含しないことを特徴とする請求項1乃至3の何れか1項に記載のエクソソーム産生促進剤。
- TNFαを包含しないことを特徴とする請求項1乃至4の何れか1項に記載のエクソソーム産生促進剤。
- 前記脂肪由来間葉系幹細胞は不織布を足場として培養されることを特徴とする請求項1乃至5の何れか1項に記載のエクソソーム産生促進剤。
- 脂肪由来間葉系幹細胞からのエクソソームの産生を促進するエクソソーム産生促進方法であって、
EGFを有する無血清培地で脂肪由来間葉系幹細胞を培養することを特徴とする、エクソソーム産生促進方法。 - 前記無血清培地に、更にIL-1βを包含することを特徴とする請求項7に記載のエクソソーム産生促進方法。
- 前記無血清培地に、更にトレハロースを包含することを特徴とする請求項7又は8に記載のエクソソーム産生促進方法。
- 前記無血清培地に、SCGFを包含しないことを特徴とする請求項7乃至9の何れか1項に記載のエクソソーム産生促進方法。
- 前記無血清培地に、TNFαを包含しないことを特徴とする請求項7乃至10の何れか1項に記載のエクソソーム産生促進方法。
- 前記脂肪由来間葉系幹細胞は不織布を足場として培養されることを特徴とする請求項7乃至11の何れか1項に記載のエクソソーム産生促進方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21945198.6A EP4324914A1 (en) | 2021-06-11 | 2021-06-11 | Exosome production promoting agent and exosome production promoting method |
PCT/JP2021/022314 WO2022259526A1 (ja) | 2021-06-11 | 2021-06-11 | エクソソーム産生促進剤及びエクソソーム産生促進方法 |
CN202180097753.7A CN117377754A (zh) | 2021-06-11 | 2021-06-11 | 外泌体产生促进剂及外泌体产生促进方法 |
KR1020237040425A KR20240000582A (ko) | 2021-06-11 | 2021-06-11 | 엑소좀 생산 촉진제 및 엑소좀 생산 촉진 방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2021/022314 WO2022259526A1 (ja) | 2021-06-11 | 2021-06-11 | エクソソーム産生促進剤及びエクソソーム産生促進方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022259526A1 true WO2022259526A1 (ja) | 2022-12-15 |
Family
ID=84425060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/022314 WO2022259526A1 (ja) | 2021-06-11 | 2021-06-11 | エクソソーム産生促進剤及びエクソソーム産生促進方法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4324914A1 (ja) |
KR (1) | KR20240000582A (ja) |
CN (1) | CN117377754A (ja) |
WO (1) | WO2022259526A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114934010A (zh) * | 2022-07-05 | 2022-08-23 | 中国人民解放军空军军医大学 | 红细胞膜在增加外泌体产量中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018182356A1 (ko) * | 2017-03-31 | 2018-10-04 | (주)안트로젠 | 중간엽줄기세포 유래 고순도, 고농도 엑소좀을 포함하는 배양액 및 이의 제조방법 |
US20190133922A1 (en) * | 2016-01-12 | 2019-05-09 | Kangstem Biotech Co., Ltd. | Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors |
WO2019088656A1 (ko) * | 2017-11-02 | 2019-05-09 | 주식회사 엑소코바이오 | 안정화된 엑소좀의 필러 조성물 |
WO2019168000A1 (ja) * | 2018-02-27 | 2019-09-06 | 国立大学法人 琉球大学 | コラゲナーゲを用いないで脂肪組織から脂肪由来幹細胞を分離抽出培養するための方法、及び脂肪由来幹細胞分離抽出用キット |
JP2019156786A (ja) | 2018-03-15 | 2019-09-19 | 株式会社ダイセル | エクソソーム産生促進剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102622643B (zh) | 2011-12-19 | 2015-12-16 | 华为终端有限公司 | 一种能通过无线网络传输数据的安全数码卡 |
-
2021
- 2021-06-11 CN CN202180097753.7A patent/CN117377754A/zh active Pending
- 2021-06-11 WO PCT/JP2021/022314 patent/WO2022259526A1/ja active Application Filing
- 2021-06-11 KR KR1020237040425A patent/KR20240000582A/ko unknown
- 2021-06-11 EP EP21945198.6A patent/EP4324914A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190133922A1 (en) * | 2016-01-12 | 2019-05-09 | Kangstem Biotech Co., Ltd. | Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors |
WO2018182356A1 (ko) * | 2017-03-31 | 2018-10-04 | (주)안트로젠 | 중간엽줄기세포 유래 고순도, 고농도 엑소좀을 포함하는 배양액 및 이의 제조방법 |
WO2019088656A1 (ko) * | 2017-11-02 | 2019-05-09 | 주식회사 엑소코바이오 | 안정화된 엑소좀의 필러 조성물 |
WO2019168000A1 (ja) * | 2018-02-27 | 2019-09-06 | 国立大学法人 琉球大学 | コラゲナーゲを用いないで脂肪組織から脂肪由来幹細胞を分離抽出培養するための方法、及び脂肪由来幹細胞分離抽出用キット |
JP2019156786A (ja) | 2018-03-15 | 2019-09-19 | 株式会社ダイセル | エクソソーム産生促進剤 |
Non-Patent Citations (7)
Title |
---|
ANONYMOUS: "The key to mass culture of stem cells was "non-woven fabric"! Regenerative Medicine Venture "Full Stem" Challenged by Brain Surgeons (ICC FUKUOKA 2020) [Transcript]", ICC SUMMIT FUKUOKA 2023, 21 June 2020 (2020-06-21), XP093017627, Retrieved from the Internet <URL:https://industry-co-creation.com/catapult/56800> [retrieved on 20230125] * |
CHAMBERLAIN GFOX JASHTON BMIDDLETON J: "Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing", STEM CELLS, vol. 25, 2007, pages 2739 - 2749, XP055018344, DOI: 10.1634/stemcells.2007-0197 |
KATSUDA TKOSAKA NTAKESHITA FOCHIYA T: "The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles", PROTEOMICS, vol. 13, 2013, pages 1637 - 1653, XP055732579, DOI: 10.1002/pmic.201200373 |
SIMONSRAPOSO, CURROPIN CELL BIOLOGY, vol. 21, 2009, pages 575 - 581 |
SKOG ET AL., NAT CELL BIOLOGY, vol. 10, 2008, pages 1470 - 1476 |
TOMOHIRO KATO;SHIGERU MIYAKI;HIROYUKI ISHITOBI;YOSHIHIRO NAKAMURA;TOMOYUKI NAKASA;MARTIN K LOTZ;MITSUO OCHI: "Exosomes from IL-1beta stimulated synovial fibroblasts induce osteoarthritic changes in articular chondrocytes", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 16, no. 4, 4 August 2014 (2014-08-04), GB , pages R163, XP021193643, ISSN: 1478-6354, DOI: 10.1186/ar4679 * |
VALADI ET AL., NAT CELL BIOLOGY, vol. 9, 2007, pages 654 - 659 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114934010A (zh) * | 2022-07-05 | 2022-08-23 | 中国人民解放军空军军医大学 | 红细胞膜在增加外泌体产量中的应用 |
CN114934010B (zh) * | 2022-07-05 | 2023-06-27 | 中国人民解放军空军军医大学 | 红细胞膜在增加外泌体产量中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP4324914A1 (en) | 2024-02-21 |
CN117377754A (zh) | 2024-01-09 |
KR20240000582A (ko) | 2024-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maqsood et al. | Adult mesenchymal stem cells and their exosomes: Sources, characteristics, and application in regenerative medicine | |
Kuhbier et al. | Isolation, characterization, differentiation, and application of adipose-derived stem cells | |
Mennan et al. | A comprehensive characterisation of large-scale expanded human bone marrow and umbilical cord mesenchymal stem cells | |
Guo et al. | Human umbilical cord mesenchymal stem cells promote peripheral nerve repair via paracrine mechanisms | |
Russo et al. | Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury | |
Blasi et al. | Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential | |
RU2562154C2 (ru) | Амниотические адгезивные клетки | |
KR101389850B1 (ko) | 심장전구세포의 배양방법 및 그 용도 | |
US20120219572A1 (en) | Spheroidal Aggregates of Mesenchymal Stem Cells | |
US20070128722A1 (en) | Human mesenchymal stem cells and culturing methods thereof | |
JP6948081B2 (ja) | エクソソーム回収方法 | |
König et al. | Placental mesenchymal stromal cells derived from blood vessels or avascular tissues: what is the better choice to support endothelial cell function? | |
Mayfield et al. | Resident cardiac stem cells and their role in stem cell therapies for myocardial repair | |
Zhou et al. | Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemic myocardium | |
Zhang et al. | Differentiation of adipose-derived stem cells toward nucleus pulposus-like cells induced by hypoxia and a three-dimensional chitosan-alginate gel scaffoldin vitro | |
Baer et al. | Expression of a functional epidermal growth factor receptor on human adipose-derived mesenchymal stem cells and its signaling mechanism | |
Meppelink et al. | Rapid isolation of bone marrow mesenchymal stromal cells using integrated centrifuge-based technology | |
WO2022259526A1 (ja) | エクソソーム産生促進剤及びエクソソーム産生促進方法 | |
Huang et al. | Enhanced migration of wharton’s jelly mesenchymal stem cells grown on polyurethane nanocomposites | |
JP7026407B2 (ja) | エクソソーム産生促進剤及びエクソソーム産生促進方法 | |
WO2008101100A2 (en) | Composition for stimulating formation of vascular structures | |
KR20130124074A (ko) | 위장관, 말초신경, 또는 혈관 기원의 중간엽줄기세포의 배양방법 및 그 용도 | |
WO2022259525A1 (ja) | エクソソーム回収方法 | |
TW202134437A (zh) | 用於預防及治療組織疾病之基於miRNA之醫藥組成物及其用途 | |
CN114127262A (zh) | 细胞外基质材料及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21945198 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180097753.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021945198 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20237040425 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237040425 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2021945198 Country of ref document: EP Effective date: 20231117 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18568061 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |